Brevan Howard Capital Management LP Has $8.69 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Brevan Howard Capital Management LP boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 196.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 97,340 shares of the medical equipment provider's stock after buying an additional 64,489 shares during the quarter. Brevan Howard Capital Management LP's holdings in Boston Scientific were worth $8,694,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. TFC Financial Management Inc. lifted its holdings in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. West Oak Capital LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth about $29,000. Valley National Advisers Inc. boosted its holdings in shares of Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after buying an additional 286 shares during the period. Fairway Wealth LLC acquired a new position in Boston Scientific in the 4th quarter valued at about $36,000. Finally, Global Trust Asset Management LLC raised its holdings in Boston Scientific by 64.5% in the 4th quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 171 shares during the period. Institutional investors own 89.07% of the company's stock.

Boston Scientific Price Performance

Shares of NYSE BSX traded down $0.42 during mid-day trading on Friday, hitting $102.87. 3,609,449 shares of the stock traded hands, compared to its average volume of 6,332,865. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17. The firm has a 50 day simple moving average of $98.68 and a two-hundred day simple moving average of $95.93. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The company has a market cap of $152.19 billion, a PE ratio of 82.30, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the prior year, the firm posted $0.56 earnings per share. The firm's revenue was up 20.9% compared to the same quarter last year. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of several research reports. Royal Bank of Canada upped their target price on Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Needham & Company LLC increased their price objective on Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Morgan Stanley boosted their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. BTIG Research reaffirmed a "buy" rating and set a $124.00 price target on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Stifel Nicolaus boosted their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, February 6th. Twenty-three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $114.52.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig sold 12,000 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total value of $1,265,760.00. Following the completion of the sale, the director now owns 24,398 shares of the company's stock, valued at approximately $2,573,501.04. This represents a 32.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the sale, the executive vice president now owns 18,705 shares in the company, valued at $1,955,420.70. The trade was a 19.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 300,497 shares of company stock worth $31,056,815. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.